Engineering A Cure for Diabetes
A.B. Lucas S.S.
This project investigated the feasibility of the cost-effective production of a human regulatory cytokine, IL-13 in transgenic plants for the treatment of Type 1 diabetes (T1D). Transgenic plants producing large amounts of IL-13 were generated. In vitro bioassays demonstrated that the plant-derived IL-13 effectively induced the proliferation of T1D-associated T-lymphocytes. Thus, this study represents a novel, low-cost, oral, immune-based therapy for diabetes.
|Honourable Mention – Biotechnology & Pharmaceutical Sciences
Sponsor: Rx&D Health Research Foundation